查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球大腸直腸癌市場評估：依治療類型、診斷、最終使用者、地區、機會、預測（2017-2031）
市場調查報告書
商品編碼
1417601

全球大腸直腸癌市場評估：依治療類型、診斷、最終使用者、地區、機會、預測（2017-2031）

Colorectal Cancer Market Assessment, By Treatment Type, By Diagnosis, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 223 Pages | 商品交期: 3-5個工作天內

價格

預計2023年全球大腸直腸癌市場規模將達150.6億美元，2031年將達207.2億美元，2024-2031年預測期間複合年增長率為4.07%。近年來，由於大腸癌盛行率的增加、醫療技術的進步和意識的提高等綜合因素，大腸直腸癌的治療和診斷市場呈現顯著增長。據世界衛生組織稱，大腸直腸癌是第三大常見癌症，約佔所有癌症的 10%。大腸直腸癌領域的研究和開發的增加正在透過新的和先進的產品推動市場。此外，強大的新藥研發管線和政府為根除癌症所做的努力預計將推動全球大腸癌市場的發展。大腸直腸癌盛行率迅速增加是由於基因突變、發炎性腸道疾病、荷爾蒙和生活方式的改變以及飲酒和吸煙造成的。導致大腸直腸癌早期檢測和治療的技術進步正在促進全球大腸直腸癌市場的成長。然而，用於治療結直腸癌的生物製劑的高昂成本以及公眾對結直腸癌缺乏認識給市場參與者帶來了挑戰。

大腸直腸癌發生率增加

全球大腸直腸癌市場的主要成長動力之一是全球大腸癌發生率的增加。這種增加可歸因於多種因素，包括久坐的生活方式、不健康的飲食、污染水平的增加以及人口老化的加劇。隨著越來越多的人在城市地區過著久坐的生活，大腸癌的盛行率持續上升，需要改進篩檢、診斷和治療解決方案。醫療保健提供者和製藥公司正在大力投資研發，以開發更有效的診斷工具和治療方法，以解決日益嚴重的健康問題。

據世界衛生組織稱，結腸癌是全球癌症相關死亡的第二大原因。根據美國臨床腫瘤學會公佈的數據，預計到 2023 年，美國將有 153,020 名成年人被診斷出罹患大腸癌。這個數字包括106,970例結腸癌（男性54,420例，女性52,550例）和46,050例直腸癌（男性27,440例，女性18,610例）。大腸直腸癌是全球第三大最常被診斷的癌症。

癌症篩檢體外診斷技術的進展

腫瘤領域醫療技術的不斷進步正在推動全球大腸癌市場的發展。PCR、原位雜交和次世代定序等體外診斷方法正在用於癌症診斷並進行最佳化，從而實現更有效的治療計劃和個人化治療選擇。此外，免疫組織化學、微陣列技術和流式細胞儀等診斷方法的突破性進展顯著改善了患者的治療結果並減少了與傳統診斷技術相關的錯誤。

這些進步正在提高大腸直腸癌患者的治療質量，並隨著製藥公司推出創新的新療法，推動市場顯著成長。2023年3月，BGI Genomics宣布與斯洛伐克地區公司Zentya合作，在斯洛伐克推出COLOTECTTM 1.0。斯洛伐克現已推出第一個大腸直腸癌糞便 DNA 檢測。COLOTECTTM 1.0 使用糞便 DNA，這是一種非侵入性篩檢測試，不僅可以檢測大腸直腸癌，還可以檢測癌前病變。COLOTECTTM 1.0 使用複雜的甲基化特異性 PCR (MSP) 技術來檢測患者糞便樣本中的大腸直腸癌生物標記。

增加資金和政府努力

政府組織、組織和機構正在透過宣傳活動積極促進大腸癌篩檢和治療，推動市場成長。研究經費的增加使得研究範圍更加廣泛，包括調查大腸直腸癌的原因、開發新的治療方法以及改進現有的治療方法。廣泛的研究和開發可以在早期檢測和更有效的治療方面取得突破，最終可以挽救生命。

本報告研究分析了全球大腸直腸癌市場，提供市場規模和預測、市場動態、主要參與者趨勢和前景等。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章 COVID-19對全球大腸直腸癌市場的影響

第 4 章執行摘要

第五章 全球大腸直腸癌市場展望（2017-2031）

  • 市場規模及預測
    • 金錢數額
    • 數量
  • 按治療類型
    • 手術
    • 放射治療
    • 化學處理
    • 靶向治療
    • 免疫療法
    • 其他治療
  • 透過診斷
    • 體外診斷測試
    • 成像
    • 切片技術
    • 其他
  • 按最終用戶
    • 癌症研究所
    • 醫院
    • 門診中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 市場佔有率：依公司劃分（2023 年）

第六章 全球大腸直腸癌市場前景：按地區劃分（2017-2031）

  • 北美
    • 市場規模及預測
    • 按治療類型
    • 透過診斷
    • 按最終用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印度尼西亞
    • 菲律賓
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合酋長國
    • 南非

第 7 章 市場測繪（2023）

  • 按治療類型
  • 透過診斷
  • 按最終用戶
  • 按地區

第八章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析 - 數量和價值
  • 供應/價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第九章市場動態

  • 增長動力
  • 成長限制因素（問題、限制因素）

第十章 監理框架與創新

  • 臨床試驗
  • 專利情況
  • 監管審批
  • 創新/新技術

第十一章 主要公司情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析（2023 年）
  • 併購/合資（如適用）
  • SWOT分析（5家進入市場的公司）
  • 專利分析（如果適用）

第12章價格分析

第十三章案例研究

第十四章 主要公司展望

  • Amgen Inc.
  • Abbott Laboratories
  • Bruker Corporation
  • Epigenomics AG
  • Clinical Genomics Technologies Pvt. Ltd.
  • VolitionRx Limited
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A
  • Quest Diagnostics Incorporated
  • Merck KGaA

第十五章 戰略建議

第十六章 關於我們公司、免責聲明

Product Code: MX10895

Global colorectal cancer market size was valued at USD 15.06 billion in 2023, and is expected to reach USD 20.72 billion in 2031, with a CAGR of 4.07% for the forecast period between 2024 and 2031F. The market for colorectal cancer therapies and diagnostics has witnessed substantial growth in recent years, driven by a combination of factors such as the increasing prevalence of colorectal cancer, advancements in medical technology, and growing awareness. According to WHO, colorectal cancer is the third most common cancer, covering about 10% of all cancer cases. Increasing research and development in the field of colorectal cancer is driving the market through new and advanced products. Additionally, a strong pipeline of new drugs and government initiatives to eradicate cancer are anticipated to drive the global colorectal cancer market. The surge in the prevalence of colorectal cancer can be attributed to inherited mutations in genes, inflammatory bowel diseases, hormonal and lifestyle changes, and alcohol and tobacco consumption. Technological advancements that result in early detection and treatment of colorectal cancer are contributing to the growth of the global colorectal cancer market. However, the high cost associated with biologics used for colorectal cancer treatment and the lack of awareness about colorectal cancer among the general population is the challenges for market players to tackle.

Increasing Incidence of Colorectal Cancer

One of the primary factors propelling the growth of global colorectal cancer market is the increase in the incidence of colorectal cancer cases across the globe. This rise can be attributed to various factors, including sedentary lifestyles, unhealthy dietary habits, increasing pollution levels, and the growing geriatric population. As more people lead increasingly urban and desk-bound lives, the prevalence of colorectal cancer continues to climb, necessitating enhanced screening, diagnosis, and treatment solutions. Healthcare providers and pharmaceutical companies invest heavily in research and development to develop more effective diagnostic tools and treatments to address growing health concerns.

As per WHO, colon cancer is the second leading cause of cancer-related deaths worldwide. According to data published by American Society of Clinical Oncology, in 2023, an estimated 153,020 adults in the United States will be diagnosed with colorectal cancer. These numbers include 106,970 new cases of colon cancer (54,420 men and 52,550 women) and 46,050 new cases of rectal cancer (27,440 men and 18,610 women). Worldwide, colorectal cancer is the third most diagnosed cancer.

Advancements in In-Vitro Diagnostic Technologies for Cancer Screening

The continuous advancements of medical technology in the field of oncology have been instrumental in driving the global colorectal cancer market. In-vitro diagnostic methods like PCR, In-situ hybridization, and next-generation sequencing are utilized and optimized for cancer diagnostics, allowing for more effective treatment planning and personalized therapy options. Moreover, breakthroughs in diagnostic methods, such as immunohistochemistry, microarray technique, and flow cytometry are significantly improving patient outcomes and reducing the errors associated with conventional diagnostics techniques.

These advancements are enhancing the quality of care for colorectal cancer patients and driving substantial growth in the market as pharmaceutical companies are launching new and innovative treatments. In March 2023, BGI Genomics announced that COLOTECTTM 1.0 would be introduced in Slovakia in collaboration with the regional business Zentya. One of the country's first fecal DNA tests for colorectal cancer has now been made available. Fecal DNA is used by COLOTECTTM 1.0, a non-invasive screening test, to detect precancerous abnormalities as well as colorectal cancer. It uses multiplex methylation-specific PCR (MSP) technology to detect colorectal cancer biomarkers in fecal samples of patients.

Increasing Funding and Government Initiatives

Government organizations, associations, and agencies are actively promoting the screening and treatment of colorectal cancer through awareness initiatives, thereby fostering market growth. Increased research grants have enabled more extensive research into the causes of colorectal cancer, development of new treatments, and improvement of existing therapies. Extensive research and development can lead to breakthroughs in early detection methods and more effective treatment options, ultimately saving lives.

The government is consistently providing research grants each year for development of novel colorectal cancer therapies. In 2021, National Cancer Institute (United States) invested USD 248 million for colorectal cancer research. As per fact sheet published by The White House, American government invested USD 394.5 million during the 2022-2023, in CDC's cancer initiatives that includes Colorectal Cancer Control Program to increase colorectal cancer screening rates among people aged 45 to 75 years.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the colorectal cancer market, affecting various aspects of research, diagnosis, treatment, and patient care. During the pandemic, many non-urgent medical procedures, including colorectal cancer screenings, were postponed, or canceled to prioritize COVID-19 patients and reduce the risk of virus transmission. The delay in screenings led to lower identification of cancer cases at more advanced stages, potentially reducing the chances of successful treatment. Many individuals with colorectal cancer or symptoms that could be an indication of the disease were postponed or avoided due to concerns about COVID-19 transmission in healthcare settings. Conclusively, the COVID-19 pandemic had a multifaceted impact on the colorectal cancer market, affecting screening, diagnosis, treatment, and patient care.

Key Players Landscape and Outlook

The landscape of key players in the colorectal cancer market includes a mix of pharmaceutical companies, medical device manufacturers, and diagnostic service providers. These organizations are actively involved in various aspects of colorectal cancer, including research, drug development, diagnostics, and treatment. The colorectal cancer market is highly dynamic, with ongoing research, drug development, and advancements in diagnostic and treatment modalities. These key players are at the forefront of efforts to combat colorectal cancer and improve patient outcomes.

For instance, Takeda and Hutchmed (China) Limited announced in May 2023 about the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, has been granted priority review by the United States Food and Drug Administration (FDA) for the treatment of adult patients with metastatic colorectal cancer that has already received prior treatment.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Colorectal Cancer Market

4. Executive Summary

5. Global Colorectal Cancer Market Outlook, 2017-2031F

  • 5.1 Market Size & Forecast
    • 5.1.1 By Value
    • 5.1.2 By Volume
  • 5.2 By Treatment Type
    • 5.2.1 Surgery
    • 5.2.2 Radiation therapy
    • 5.2.3 Chemotherapy
      • 5.2.3.1 Alkylating Agents
      • 5.2.3.2 Antimetabolites
      • 5.2.3.3 Others
    • 5.2.4 Targeted therapy
    • 5.2.5 Immunotherapy
      • 5.2.5.1 Panitumumab
      • 5.2.5.2 Cetuximab
      • 5.2.5.3 Bevacizumab
      • 5.2.5.4 Others
    • 5.2.6 Other Treatments
  • 5.3 By Diagnosis
    • 5.3.1 In-vitro Diagnostic Testing
      • 5.3.1.1 Polymerase Chain Reaction (PCR)
      • 5.3.1.2 Blood Test
      • 5.3.1.3 In-situ Hybridization (ISH)
      • 5.3.1.4 Immunohistochemistry
      • 5.3.1.5 Next-generation Sequencing (NGS)
      • 5.3.1.6 Microarrays
      • 5.3.1.7 Flow Cytometry
      • 5.3.1.8 Immunoassays
      • 5.3.1.9 Other In-vitro Diagnostic Testing Technologies
    • 5.3.2 Imaging
      • 5.3.2.1 Magnetic Resonance Imaging (MRI)
      • 5.3.2.2 Computed Tomography (CT)
      • 5.3.2.3 Positron Emission Tomography (PET)
      • 5.3.2.4 Mammography
      • 5.3.2.5 Ultrasound
    • 5.3.3 Biopsy Technologies
    • 5.3.4 Others
  • 5.4 By End-user
    • 5.4.1 Cancer Research Institutes
    • 5.4.2 Hospitals
    • 5.4.3 Ambulatory Care Centers
    • 5.4.4 Others
  • 5.5 By Region
    • 5.5.1 North America
    • 5.5.2 Europe
    • 5.5.3 Asia Pacific
    • 5.5.4 South America
    • 5.5.5 Middle East & Africa
  • 5.6 By Company Market Share (%), 2023

6. Global Colorectal Cancer Market Outlook, By Region, 2017-2031F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Treatment Type
      • 6.1.2.1. Surgery
      • 6.1.2.2. Radiation therapy
      • 6.1.2.3. Chemotherapy
      • 6.1.2.3.1. Alkylating Agents
      • 6.1.2.3.2. Antimetabolites
      • 6.1.2.3.3. Others
      • 6.1.2.4. Targeted therapy
      • 6.1.2.5. Immunotherapy
      • 6.1.2.5.1. Panitumumab
      • 6.1.2.5.2. Cetuximab
      • 6.1.2.5.3. Bevacizumab
      • 6.1.2.5.4. Others
      • 6.1.2.6. Other Treatments
    • 6.1.3. By Diagnosis
      • 6.1.3.1. In-vitro Diagnostic Testing
      • 6.1.3.1.1. Polymerase Chain Reaction (PCR)
      • 6.1.3.1.2. Blood Test
      • 6.1.3.1.3. In-situ Hybridization (ISH)
      • 6.1.3.1.4. Immunohistochemistry
      • 6.1.3.1.5. Next-generation Sequencing (NGS)
      • 6.1.3.1.6. Microarrays
      • 6.1.3.1.7. Flow Cytometry
      • 6.1.3.1.8. Immunoassays
      • 6.1.3.1.9. Other In-vitro Diagnostic Testing Technologies
      • 6.1.3.2. Imaging
      • 6.1.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.3.2.2. Computed Tomography (CT)
      • 6.1.3.2.3. Positron Emission Tomography (PET)
      • 6.1.3.2.4. Mammography
      • 6.1.3.2.5. Ultrasound
      • 6.1.3.3. Biopsy Technologies
      • 6.1.3.4. Others
    • 6.1.4. By End-user
      • 6.1.4.1. Cancer Research Institutes
      • 6.1.4.2. Hospitals
      • 6.1.4.3. Ambulatory Care Centers
      • 6.1.4.4. Others
    • 6.1.5. United States*
      • 6.1.5.1. Market Size & Forecast
      • 6.1.5.1.1. By Value
      • 6.1.5.1.2. By Volume
      • 6.1.5.2. By Treatment Type
      • 6.1.5.2.1. Surgery
      • 6.1.5.2.2. Radiation therapy
      • 6.1.5.2.3. Chemotherapy
      • 6.1.5.2.3.1. Alkylating Agents
      • 6.1.5.2.3.2. Antimetabolites
      • 6.1.5.2.3.3. Others
      • 6.1.5.2.4. Targeted therapy
      • 6.1.5.2.5. Immunotherapy
      • 6.1.5.2.5.1. Panitumumab
      • 6.1.5.2.5.2. Cetuximab
      • 6.1.5.2.5.3. Bevacizumab
      • 6.1.5.2.5.4. Others
      • 6.1.5.2.6. Other Treatments
      • 6.1.5.3. By Diagnosis
      • 6.1.5.3.1. In-vitro Diagnostic Testing
      • 6.1.5.3.1.1. Polymerase Chain Reaction (PCR)
      • 6.1.5.3.1.2. Blood Test
      • 6.1.5.3.1.3. In-situ Hybridization (ISH)
      • 6.1.5.3.1.4. Immunohistochemistry
      • 6.1.5.3.1.5. Next-generation Sequencing (NGS)
      • 6.1.5.3.1.6. Microarrays
      • 6.1.5.3.1.7. Flow Cytometry
      • 6.1.5.3.1.8. Immunoassays
      • 6.1.5.3.1.9. Other In-vitro Diagnostic Testing Technologies
      • 6.1.5.3.2. Imaging
      • 6.1.5.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.5.3.2.2. Computed Tomography (CT)
      • 6.1.5.3.2.3. Positron Emission Tomography (PET)
      • 6.1.5.3.2.4. Mammography
      • 6.1.5.3.2.5. Ultrasound
      • 6.1.5.3.3. Biopsy Technologies
      • 6.1.5.3.4. Others
      • 6.1.5.4. By End-user
      • 6.1.5.4.1. Hospitals
      • 6.1.5.4.2. Cancer Research Institutes
      • 6.1.5.4.3. Ambulatory Care Centers
      • 6.1.5.4.4. Others
    • 6.1.6. Canada
    • 6.1.7. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Treatment Type
  • 7.2. By Diagnosis
  • 7.3. By End-user
  • 7.4. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Amgen Inc.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Abbott Laboratories
  • 14.3. Bruker Corporation
  • 14.4. Epigenomics AG
  • 14.5. Clinical Genomics Technologies Pvt. Ltd.
  • 14.6. VolitionRx Limited
  • 14.7. F. Hoffmann-La Roche Ltd
  • 14.8. Sanofi S.A
  • 14.9. Quest Diagnostics Incorporated
  • 14.10. Merck KGaA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 4. Global Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 5. Global Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Colorectal Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 10. North America Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 11. North America Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 16. United States Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 17. United States Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 21. Canada Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 22. Canada Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 26. Mexico Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 27. Mexico Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 31. Europe Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 32. Europe Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 37. Germany Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 38. Germany Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 42. France Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 43. France Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 47. Italy Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 48. Italy Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 52. United Kingdom Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 53. United Kingdom Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 57. Russia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 58. Russia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 62. Netherlands Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 63. Netherlands Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 67. Spain Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 68. Spain Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 72. Turkey Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 73. Turkey Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 77. Poland Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 78. Poland Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 82. South America Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 83. South America Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 88. Brazil Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 89. Brazil Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 93. Argentina Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 94. Argentina Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 98. Asia-Pacific Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 99. Asia-Pacific Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101. India Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 104. India Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 105. India Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 109. China Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 110. China Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 114. Japan Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 115. Japan Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 119. Australia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 120. Australia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 124. Vietnam Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 125. Vietnam Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 129. South Korea Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 130. South Korea Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 134. Indonesia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 135. Indonesia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 139. Philippines Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 140. Philippines Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 144. Middle East & Africa Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 145. Middle East & Africa Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 150. Saudi Arabia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 151. Saudi Arabia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 155. UAE Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 156. UAE Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 160. South Africa Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 161. South Africa Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023